2seventy Appoints Steven Bernstein as Their New CMO; Susan Abu-Absi Appointed as 2seventy’s Chief Technology and Manufacturing Officer

On Monday, February 14, 2seventy bio announced (press release) the appointment of Steven Bernstein as Chief Medical Officer (CMO) and Susan Abu-Absi as Chief Technology and Manufacturing Officer. Below, Celltelligence provides insights on how 2seventy could leverage Bernstein’s translational clinical background to bring novel assets into the clinic, while discussing the company’s decision to create a Chief Technology and Manufacturing Officer position. 

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.